• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Frontiers in Public Health >SGLT-2i and Risk of Malignancy in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials
【24h】

SGLT-2i and Risk of Malignancy in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials

机译：SGLT-2I和2型糖尿病中恶性肿瘤的风险：随机对照试验的META分析

获取原文
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Currently, the association between sodium-glucose cotransporter 2 inhibitor (SGLT-2i) and malignancy risk has yet to be fully elucidated. This meta-analysis aimed to determine the relationship between SGLT-2i and malignancy risk in type 2 diabetes (T2D) patients. Methods: We searched PubMed, ScienceDirect, EMBASE, Cochrane Central Register of Controlled Trials, and Web of Science to identify randomized controlled trials (RCTs) published up to August 2020 related to T2D patients treated with SGLT-2i vs. placebo or other hypoglycemic agents. The meta-analysis's primary outcome was malignancies' incidence, and the results were evaluated using risk ratio (RR) and 95% confidence interval (CI). Results: We reviewed 76 articles (77 RCTs), comprising 45,162 and 43,811 patients in SGLT-2i and control groups, respectively. Compared with the control group, SGLT-2i had no significant association with augmented overall malignancy risk in T2D patients (RR = 1.05, 95% CI = 0.97–1.14, P = 0.20), but ertugliflozin may upsurge the risk (RR = 1.80, 95% CI = 1.02–3.17, P = 0.04). Compared with active hypoglycemic agents, dapagliflozin may increase (RR = 2.71, 95% CI = 1.46–6.43, P = 0.02) and empagliflozin may decrease (RR = 0.67, 95% CI = 0.45–0.98, P = 0.04) the malignancy risk. Compared with placebo, empagliflozin may exhibit risk increase (RR = 1.25, 95% CI = 1.05–1.49, P = 0.01), primarily in digestive system (RR = 1.48, 95% CI = 0.99–2.21, P = 0.05). Conclusions: Our results proposed that in diverse comparisons, ertugliflozin and dapagliflozin seemed to increase the malignancy risk in T2D patients. Empagliflozin may cause malignancy risk reduction compared with active hypoglycemic agents but increase overall risk primarily in the digestive system compared with placebo. In short, the relationship between SGLT-2i and malignancy in T2D patients remains unclear.
机译：背景：目前，钠葡萄糖Cotoransporter 2抑制剂（SGLT-2I）和恶性风险之间的关联尚未完全阐明。该荟萃分析旨在确定2型糖尿病（T2D）患者的SGLT-2I和恶性风险之间的关系。方法：我们搜索了PubMed，ScieCentirect，Embase，Cochrane中央登记册，科学网站和科学网，以确定高达2020年8月20日发布的随机对照试验（RCT），与SGLT-2I与安慰剂或其他降血糖药物治疗的T2D患者有关。 Meta分析的主要结果是恶性肿瘤的发病率，并使用风险比（RR）和95％置信区间（CI）评估结果。结果：我们审查了76篇文章（77个RCT），分别在SGLT-2I和对照组中患者组成，包括45,162和43,811名。与对照组相比，SGLT-2I与T2D患者的增强总体恶性风险没有显着关联（RR = 1.05,95％CI = 0.97-1.14，P = 0.20），但埃尔图利洛素可能会振荡风险（RR = 1.80， 95％CI = 1.02-3.17，P = 0.04）。与活性降糖剂相比，Dapagliflozin可以增加（RR = 2.71,95％CI = 1.46-6.43，P = 0.02）和Empagliflozin可能降低（RR = 0.67,95％CI = 0.45-0.98，P = 0.04）恶性风险。与安慰剂相比，Empagliflozin可能表现出风险增加（RR = 1.25,95％CI = 1.05-1.49，P = 0.01），主要是消化系统（RR = 1.48,95％CI = 0.99-21，P = 0.05）。结论：我们的研究结果提出，在不同的比较中，Ertugliflozin和Dapagliflozin似乎增加了T2D患者的恶性风险。与活性降血糖药物相比，empagliflozin可能导致恶性风险降低，但与安慰剂相比，主要在消化系统中提高整体风险。简而言之，T2D患者中SGLT-2I与恶性肿瘤之间的关系仍然尚不清楚。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号